[Combination of internal and external beam radiotherapy].

Combinaison de la radiothérapie interne vectorisée et de la radiothérapie externe.
CIERT Cancer Dosimetry Dosimétrie Radio-immunothérapie Radiobiologie Radiobiology Radioimmunotherapy Radioligands Radionuclide therapy Radiothérapie interne vectorisée Radiothérapie interne vectorisée associée à la radiothérapie externe

Journal

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique
ISSN: 1769-6658
Titre abrégé: Cancer Radiother
Pays: France
ID NLM: 9711272

Informations de publication

Date de publication:
Dec 2023
Historique:
received: 30 05 2023
revised: 17 08 2023
accepted: 23 08 2023
medline: 4 12 2023
pubmed: 13 11 2023
entrez: 12 11 2023
Statut: ppublish

Résumé

External beam radiation therapy and internal vectorized radiation therapy are two types of radiotherapy that can be used to treat cancer. They differ in the way they are administered, and the type of radiation used. Although they can be effective in treating cancer, they each have their own advantages and disadvantages, and their combination could be synergistic. Preclinical studies on combined internal and external beam radiation therapy have mainly used radiolabelled antibodies, whose bone marrow toxicity remains the limiting factor in increasing the administered activities. The use of small radioligands in clinical trials has shown to be better tolerated and more effective, which explains their rapid development. The results of preclinical studies on combined internal and external beam radiation therapy appear heterogeneous, making it impossible to determine an ideal therapeutic sequencing scheme, and complicating the transposition to clinical studies. The few clinical studies on combined internal and external beam radiation therapy available to date have demonstrated feasibility and tolerability. More work remains to be done in the fields of dosimetry and radiobiology, as well as in the sequencing of these two irradiation modalities to optimize their combination.

Identifiants

pubmed: 37953187
pii: S1278-3218(23)00216-0
doi: 10.1016/j.canrad.2023.08.005
pii:
doi:

Types de publication

English Abstract Journal Article Review

Langues

fre

Sous-ensembles de citation

IM

Pagination

754-758

Informations de copyright

Copyright © 2023. Published by Elsevier Masson SAS.

Auteurs

A-L Giraudet (AL)

Centre Léon-Bérard, 15, rue Gabriel-Sarrazin, 69008 Lyon, France. Electronic address: annelaure.giraudet@lyon.unicancer.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH